The effect of empagliflozin on all-cause mortality and hospitalization for heart failure will be evaluated in the in phase 3 EMPACT-MI study.
Researchers used data from the National Health and Nutrition Examination Survey 2009-2018 to assess the impact of drug and alcohol use on cardiometabolic disease risk factors.
High-density lipoprotein cholesterol efflux capacity may be impaired in patients with severe short-term hypothyroidism.
Exposure to maternal polycystic ovary syndrome (PCOS) is associated with increased risk of a range of neurodevelopmental and psychiatric disorders in offspring.
Researchers sought to determine whether triglyceride levels were independently associated with cardiovascular disease among patients with coronary artery disease and type 2 diabetes.
The multicenter, double-blind, placebo-controlled HAUSER-RCT study assessed the efficacy and safety of evolocumab in 157 patients aged 10 to 17 years with HeFH.
Metabolic syndrome (MetS) is associated with a lethal outcome for patients with COVID-19.
The post-hoc analysis included 2 placebo-controlled phase 3 studies (ORION-10 and -11) that evaluated the efficacy and safety of inclisiran sodium in more than 2300 adult patients.
Elevated plasma levels of lipoprotein(a) and family history of coronary heart disease (CHD) were found to be associated with a risk for cardiovascular disease.
Researchers used electronic health records to further understand the clinical features and gaps in treatment approaches for patients with severe hypercholesterolemia.
Pitavastatin lowers blood total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides in a dose-dependent manner.